The use of hepatocytes in evaluating time-dependent inactivation of P450 in vivo (Q37106069)

18 August 2017

1 reference

title

The use of hepatocytes in evaluating time-dependent inactivation of P450 in vivo (English)

1 reference

18 August 2017

Ping Zhao

1

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 February 2008

1 reference

Expert Opinion on Drug Metabolism & Toxicology

18 August 2017

published in

1 reference

18 August 2017

volume

4

1 reference

18 August 2017

issue

2

1 reference

18 August 2017

page(s)

151-164

1 reference

Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance.

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Use of isolated hepatocyte preparations for cytochrome P450 inhibition studies: comparison with microsomes for Ki determination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Demethylation of radiolabelled dextromethorphan in rat microsomes and intact hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Altered AZT (3'-azido-3'-deoxythymidine) glucuronidation kinetics in liver microsomes as an explanation for underprediction of in vivo clearance: comparison to hepatocytes and effect of incubation environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Prediction of CYP2C9-mediated drug-drug interactions: a comparison using data from recombinant enzymes and human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Protein covalent binding of maxipost through a cytochrome P450-mediated ortho-quinone methide intermediate in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Kinetic values for mechanism-based enzyme inhibition: assessing the bias introduced by the conventional experimental protocol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Role of itraconazole metabolites in CYP3A4 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Sequential metabolism is responsible for diltiazem-induced time-dependent loss of CYP3A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Mechanism-based inactivation of CYP3A by HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Time response of cytochrome P450 1A2 activity on cessation of heavy smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Database analyses for the prediction of in vivo drug-drug interactions from in vitro data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Enhanced effect of triazolam with diltiazem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

N-monodesmethyldiltiazem is the predominant metabolite of diltiazem in the plasma of young and elderly hypertensives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Time-dependent CYP inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

Characterizing uncertainty and variability in physiologically based pharmacokinetic models: state of the science and needs for research and implementation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.2.151

21 January 2018

Identifiers

DOI

10.1517/17425255.4.2.151

1 reference

18 August 2017

1 reference